Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMO | O15229 | 9/20 | 0.41 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.36 |
| ▸ | SMARCA2 | P51531 | 2/20 | 0.33 |
| ▸ | SMARCA4 | P51532 | 2/20 | 0.33 |
| ▸ | KDM5A | P29375 | 1/20 | 0.33 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.32 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL287227 | 0.83 | KMO (0.58) | KMONAPRT | |
| SCHEMBL1206986 | 0.81 | MAP4K4 (0.40) | KMOSIRT6ALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL8159378 | 0.81 | SORD (0.44) | KMOSMARCA2SMARCA4ALDH1A1SMN1; SMN2 | |
| SCHEMBL21173935 | 0.78 | KMO (0.37) | KMONAPRTKDM5AKDM4CALDH1A1 | |
| SCHEMBL30368390 | 0.78 | KMO (0.37) | KMONAPRTKDM5AKDM4CALDH1A1 | |
| SCHEMBL24087665 | 0.77 | KMO (0.37) | KMONAPRTALDH1A1 | |
| SCHEMBL27956903 | 0.77 | KMO (0.36) | KMOALDH1A1SMN1; SMN2 | |
| SCHEMBL18824676 | 0.76 | ALDH1A1 (0.40) | KMOALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL282078 | 0.76 | L3MBTL1 (0.38) | KMOSMARCA2SMARCA4GAASMN1; SMN2 | |
| SCHEMBL31589417 | 0.76 | P2RX7 (0.57) | KMOKDM5AALDH1A1GAALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4370512-A1 | CD38 MODULATORS AND METHODS OF USE THEREOF | Cytokinetics, Inc. (US) | 2024-05-22 | — | — | EP | disclosed |
| CN-117813296-A | CD38 modulators and methods of use thereof | 赛特凯恩蒂克公司 | 2024-04-02 | — | — | CN | disclosed |
| WO-2023114977-A1 | S1PR4 RECEPTOR ANTAGONISTS AND METHODS OF USE THEREOF | TIAKI THERAPEUTICS, INC. (US) | 2023-06-22 | — | — | WO | disclosed |
| US-20230116972-A1 | CD38 MODULATORS AND METHODS OF USE THEREOF | CYTOKINETICS, INC. | 2023-04-20 | — | — | US | disclosed |
| US-20230116972-A1 | CD38 MODULATORS AND METHODS OF USE THEREOF | CYTOKINETICS, INC. | 2023-04-20 | — | — | US | disclosed |
| WO-2023288195-A1 | CD38 MODULATORS AND METHODS OF USE THEREOF | CYTOKINETICS, INC. (US) | 2023-01-19 | — | — | WO | disclosed |
| CN-101372475-B | Aromatic heterocyclic substituted diphenyl urea derivative and application thereof | NANJING UNIVERSITY OF TECHNOLOGY | 2012-01-04 | — | — | CN | disclosed |
| EP-2183224-A1 | 6-AMINO-PYRIMIDINE-4-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS WHICH BIND TO THE SPHINGOSINE 1-PHOSPHATE (S1P) RECEPTOR FOR THE TREATMENT OF MULTIPLE SCLEROSIS | Merck Serono S.A. (CH) | 2010-05-12 | — | — | EP | disclosed |
| CN-101372475-A | Aromatic heterocyclic substituted diphenyl urea derivative and application thereof | NANJING UNIVERSITY OF TECHNOLOGY (CN) | 2009-02-25 | — | — | CN | disclosed |
| WO-2009019167-A1 | 6-AMINO-PYRIMIDINE-4-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS WHICH BIND TO THE SPHINGOSINE 1-PHOSPHATE (S1P) RECEPTOR FOR THE TREATMENT OF MULTIPLE SCLEROSIS | MERCK SERONO S.A. (CH) | 2009-02-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230116972-A1 | CD38 MODULATORS AND METHODS OF USE THEREOF | CD38, CXCR4, FCGRT | KMO 3243/4885NAPRT 833/4885SMARCA2 3878/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.